1. Introduction {#s0005}
===============

Xerostomia, taste impairment, and dysphagia are common late radiation-associated side effects that can negatively impact the quality of life of head and neck cancer (HNC) survivors [@b0005], [@b0010], [@b0015], and the severity of these oral-related toxicities has been shown to be related in part to radiotherapy (RT) dose delivered to the oral tongue and its associated mucosa, salivary glands, and musculature [@b0020], [@b0025], [@b0030].

Oral stents can be used during RT for oropharyngeal cancer (OPC) to better position the oral tissues to facilitate normal tissue sparing and/or immobilize the tongue. For example, tongue-deviating oral stents can be used to displace the non-target oral tongue away from the target volume, such as in well-lateralized tonsil cancers treated with unilateral neck RT. Tongue-depressing oral stents can be used in base of tongue (BOT) cancers to displace the BOT target volume away from the non-target palate and help to immobilize the tongue to facilitate tongue/target position reproducibility [@b0035] and accurate RT delivery.

While patient-specific custom oral stents, fabricated by our dental oncologists, are commonly used at our center for the treatment of OPC based on the aforementioned rationale and the demonstrated dosimetric advantages [@b0040], [@b0045], [@b0050], [@b0055], [@b0060], [@b0065], [@b0070], the use of custom oral stents may not be routinely used in many radiation oncology practices owing to availability of dental expertise/resources or lack of studies demonstrating clinical benefit in terms of late toxicity reduction. In recent years, pre-fabricated commercial stent products became available and stent fabrication became easier and less time consuming with the innovation of 3D printers [@b0075], [@b0080], [@b0085]. However, 3D printers in hospitals are still not common devices.

As part of an ongoing effort by our MD Anderson Head and Neck Cancer Symptom Working Group to profile patient reported symptoms and outcomes in HNC survivors and to advance clinical practice by developing strategies to reduce RT-associated toxicities, the specific aim of the present study was to assess whether the use of oral stents is associated with oral morbidity-related patient reported symptoms in OPC survivors after treatment with intensity modulated radiation therapy (IMRT).

2. Material and methods {#s0010}
=======================

2.1. Study procedure {#s0015}
--------------------

Adult HNC patients who had received RT with curative intent, who were without evidence of active disease and had completed initial therapy more than 6 months previously were eligible to participate in an Institutional Review Board (IRB)-approved, single institution, prospective longitudinal symptom assessment study. Study-specific informed consent was provided by all participants, who then either self-completed patient reported outcome questionnaires via pencil/paper during follow-up visit or via telephone interview conducted by study personnel using a study-specific IRB-approved script.

The current study is based on a cross-sectional sample of the aforementioned study using the validated MD Anderson Symptom Inventory - Head and Neck module (MDASI-HN) [@b0090]. In the current study we analyzed six potentially oral morbidity-related items of the MDASI-HN completed at a minimum of 12 months after completion of IMRT (including volumetric arc radiation therapy \[VMAT\]) for treatment of tonsil or BOT squamous cell carcinoma. These items were: problem tasting food, dry mouth, mucus in mouth/throat, difficulty swallowing/chewing, mouth/throat sores, and lack of appetite.

Since the patients' symptoms had been assessed at various time points in the post-RT follow-up period with the MDASI-HN, we used the last assessment for our analysis in patients who had no cancer events subsequent to treatment. The last MDASI-HN has been chosen, as our group previously showed, that even after years from RT there is still potential for improvement of late radiation-associated symptoms like taste impairment [@b0095]. For patients who developed local/regional recurrence, received systemic therapy for distant metastases or second malignancy, or had oral surgery in the follow-up period, we used the last MDASI before this event or otherwise excluded the patient if this MDASI was completed within the first year post-RT (Suppl. Table 1). Patients excluded from this analysis were those with missing information regarding oral immobilization.

The symptom items are rated by patients on an 11-point Likert scale from 0 ("not present") to 10 ("as bad as you can imagine"), indicating the presence and severity of the symptoms over the past 24 hours. Symptom ratings were considered mild with a score of 1--4, moderate 5--6 and severe 7--10. Patient demographics and tumor and treatment characteristics were extracted from the electronic medical record. Tumor category is described according to the current cancer staging manual of the American Joint Committee on Cancer (AJCC) at the time of the initial diagnosis.

2.2. Patient treatment {#s0020}
----------------------

All patients had undergone CT simulation and were immobilized for simulation and treatment using a customized thermoplastic head, neck and shoulder mask with or without a customized oral stent at the discretion of the treating radiation oncologist. Use of stent was considered for patients who could safely and reliably tolerate stent use and achieve oral immobilization and/or displacement. A customized mouth-opening and tongue-depressing oral stent was generally used for patients with BOT primaries and a tongue-deviating oral stent for patients with small tonsil primaries or those confined to the tonsillar fossa ([Fig. 1](#f0005){ref-type="fig"}).Fig. 1Tongue-deviating stent (A/blue arrow) and tongue-depressing stent (B/orange arrow) with representative sagittal and axial CT simulation images of patients. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

All patients had received IMRT (or VMAT) with 6 MV photons. Patients with well-lateralized T1-T2 tonsil primaries without evidence of contralateral nodal disease were generally treated with unilateral neck RT [@b0100]; all others were generally treated with bilateral neck RT.

2.3. Statistical analysis {#s0025}
-------------------------

All statistical analyses were performed with IBM SPSS Statistics 24 (IBM, Armonk, NY) and JMP Pro 14 (SAS Institute, Cary, NC). Descriptive statistics were used for description of patient population and symptom ratings. Mann-Whitney U and Kruskal-Wallis test were performed for non-parametric group comparison analyses. Spearman rho test was applied to test for correlation between symptoms. Univariate analysis was used for selection of confounding factors on symptoms (no/mild vs. moderate/severe), which were then investigated in the multivariate analysis if more than one factor had a p-value below 0.1 (both nominal logistic regression). A non-Bonferroni corrected p-value of \<0.05 was considered as significant for this hypothesis generating study.

3. Results {#s0030}
==========

Four hundred sixty-two OPC survivors formed the cohort. Eighty-three percent were male, 17% female, with a median age of 55 years. The median follow-up from end of RT (2001--2015) to MDASI-HN assessment (collected from 2010 to 2019) was 68 months (range 13--158).

Two hundred forty-eight patients (54%) had tonsil primaries and 214 (46%) BOT. Most had T1 (36%) --T2 (39%) tumors and 91% were node positive. The most common radiation treatment fractionation schedules were 66 Gy in 30 fractions (48%), and 70 Gy in 33 fractions (36%). Chemotherapy was used in 45% of patients (including induction, concurrent and/or adjuvant chemotherapy) and 13% received concurrent targeted therapy. Details of the patient population are displayed in [Table 1](#t0005){ref-type="table"}.Table 1Patient and treatment characteristics of the study cohort (n = 462 patients). n (%)\*Sex Male385 (83.3%) Female77 (16.7%)Age at RT start \[years\] Mean/SD56/9 Median55 Range29--84Race Caucasian448 (97.0%) Asian3 (0.6%) Black or African American7 (1.5%) American Indian or Alaska Native2 (0.4%) Unavailable2 (0.4%)Primary tumor site Tonsil248 (53.7%) BOT214 (46.3%)Tumor category Tis1 (0.2%) T1168 (36.4%) T2181 (39.2%) T372 (15.6%) T435 (7.6%) Unavailable5 (1.1%)Nodal status N040 (8.7%) N+422 (91.3%)Tumor HPV or p16 Positive222 (48.0%) Negative22 (4.8%) Unknown218 (47.2%)PTV1 \[Gy\] Mean/SD67.9/2.4 Median66 Range57.6--72.5Number of fractions Mean/SD31.9/2.6 Median30 Range27--40Chemotherapy Any256 (44.6%) Induction152 (32.9%) Concurrent156 (33.8%) Adjuvant5 (1.1%)Targeted therapy Concurrent58 (12.6%)Smoking status at RT start Current smoker31 (6.7%) Former smoker173 (37.4%) Never smoker204 (44.2%) Unavailable54 (11.7%)[^1]

Unilateral neck RT was delivered in 94 patients with tonsil cancer (20% of the whole cohort; 38% of the tonsil cancer patients). In these, 49 (53%) were treated with a tongue-deviating stent. Bilateral RT was received by 364 patients; 152 with tonsil cancer (20% of them with tongue-deviating stent, 16% with tongue-depressing stent) and 212 with BOT primary (85% with tongue-depressing stent) (Suppl. Table 1).

3.1. Long-term patient reported symptoms {#s0035}
----------------------------------------

The topmost severe symptom was dry mouth (mean rating: 3.89), followed by difficulty swallowing/chewing (2.70), mucus in mouth/throat (2.15), problem tasting food (1.82), lack of appetite (0.90) and mouth/throat sores (0.49) (Suppl. Table 2). Moderate/severe symptom ratings were reported by 39% of the patients for dry mouth, 24% for difficulty swallowing/chewing, 19% for mucus in mouth/throat and 16% for problem tasting food; the percentage of patients with moderate/severe ratings for lack of appetite and mouth/throat sores was less than 10% ([Fig. 2](#f0010){ref-type="fig"}, Suppl. Table 2). There was a highly significant correlation between all symptoms analyzed (p \< 0.001) (Suppl. Table 3).Fig. 2Percentage of OPC survivors having no, mild, moderate and severe long-term symptoms according to the MDASI-HN questionnaire (n = 462).

3.2. Effect of radiation technique {#s0040}
----------------------------------

Patients with T1--2 tonsil cancer treated with unilateral neck RT had lower mean MDASI-HN scores compared to patients treated bilaterally for all the reported symptoms except for mouth/throat sores (Suppl. Table 4).

For problem tasting food, mouth/throat mucus, and lack of appetite, about half as many patients reported moderate/severe ratings treated with unilateral vs. bilateral neck RT (6.5 vs. 15.0%, 8.3% vs. 17.5%, 3.1 vs. 9.2%; respectively, Suppl. Table 4).

3.3. Effect of oral stent {#s0045}
-------------------------

For those patients who received unilateral neck RT, there was a significant difference in the number of patients in the different MDASI-HN categories (no, mild, moderate, severe) for taste impairment when comparing patients with tongue-deviating stent versus no stent (p = 0.047, [Fig. 3](#f0015){ref-type="fig"}). Thirteen percent of patients treated without stent reported severe taste impairment whereas no patient treated with a tongue-deviating stent had severe problems tasting food. The mean MDASI-HN score for taste was 0.51 versus 1.74 in patients with and without stent, respectively ([Table 2](#t0010){ref-type="table"}). Appetite was also significantly better in patients treated with a tongue-deviating stent ([Table 2](#t0010){ref-type="table"}, [Fig. 3](#f0015){ref-type="fig"}). Both symptoms, taste impairment and lack of appetite, were significantly less with the oral stent when comparing the groups with no/mild versus moderate/severe symptoms (taste impairment: p = 0.027, lack of appetite: p = 0.030). Patients with a tongue-deviating stent had significantly earlier T-category than patients without stent (T1: 79% vs. 59%, respectively, Suppl. Table 5), but when subgrouping by T-category (T1 and T2) lower MDASI-HN taste impairment and lack of appetite scores for each stage were still observed (Suppl. Table 6).Fig. 3Severity of taste impairment and lack of appetite for patients treated with unilateral radiotherapy with and without tongue-deviating stent.Table 2MDASI-HN symptom ratings according to neck RT laterality and stent use. MDASI-HN scores of ≥1 and ≤4 are considered as mild, ≥5 and ≤6 moderate and ≥7 severe symptoms.Unilateral radiotherapyBilateral radiotherapyMDASI-HN scores/symptom categoriesTongue-deviating stentNo stentp-value (no vs. tongue-deviating stent)Tongue-depressing stentNo stentp-value (no vs. tongue-depressing stent)Number of patients4943205129Taste impairmentMean/SD0.51/1.161.74/3.140.0562.20/2.771.92/2.520.555Median0011Range0--50--100--100--10No77.10%62.50%**0.047**43.00%43.10%0.773Mild20.80%22.50%37.00%39.00%Moderate2.10%2.50%9.00%10.60%Severe0%12.50%11.00%7.30%Dry mouthMean/SD3.08/2.913.38/3.190.7074.20/2.974.04/2.990.604Median22.543Range0--100--100--100--10No18.40%20.90%0.90511.20%10.20%0.747Mild55.10%51.20%44.40%49.60%Moderate12.20%9.30%20.50%15.70%Severe14.30%18.60%23.90%24.40%Mucus in mouth/throatMean/SD1.54/2.141.33/2.410.3732.25/2.592.58/2.810.335Median0012Range0--90--100--100--10No53.10%62.80%0.33737.80%33.90%0.377Mild34.70%30.20%41.80%42.50%Moderate10.20%0.00%10.00%10.20%Severe2.00%7.00%10.40%13.40%Difficulty swallowing/Mean/SD1.83/2.652.81/3.040.0682.53/2.543.28/2.78**0.013**chewingMedian11.523Range0--100--100--100--10No44.90%30.20%0.08528.80%19.40%**0.013**Mild38.80%41.90%50.20%50.00%Moderate6.10%16.30%11.20%12.90%Severe10.20%11.60%9.80%17.70%Mouth/throat soresMean/SD0.65/1.770.69/1.630.6060.37/1.240.55/1.26**0.023**Median0000Range0--90--100--80--7No81.60%76.70%0.57784.40%75.00%**0.028**Mild14.30%18.60%11.20%22.70%Moderate0%2.30%2.40%1.60%Severe4.10%2.30%1.00%0.80%Lack ofMean/SD0.17/0.661.02/2.27**0.018**0.96/2.051.12/2.170.242appetiteMedian0000Range0--40--100--100--10No91.80%74.40%**0.019**73.60%66.70%0.199Mild8.20%16.30%18.90%25.40%Moderate0%4.70%4.00%2.40%Severe0%4.70%3.50%5.60%[^2][^3]

One hundred eighty patients (88%) with BOT cancers were treated with bilateral RT and a tongue-depressing stent compared with only 25 patients (12%) with tonsillar cancer (p \< 0.001, Suppl. Table 5).

Patients with bilateral radiotherapy treated with a tongue-depressing stent reported significantly less swallowing/chewing difficulty and fewer mouth/throat sores ([Table 2](#t0010){ref-type="table"}): Ten percent of patients treated with a tongue-depressing stent reported severe dysphagia after therapy, compared to 18% treated without an oral stent (p = 0.013 for comparison of the severity categories). Regarding mouth/throat sores, 84% of patients had no symptoms if treated with a tongue-depressing stent compared to 75% of patients treated without a stent (p = 0.028 for comparison of the severity categories). When the symptom severity groups were merged together to no/mild versus moderate/severe toxicity, swallowing/chewing difficulty remained significantly different between patients treated with or without stent (p = 0.049).

3.4. Multivariate analysis of patient and treatment factors on oral morbidity-related symptoms {#s0050}
----------------------------------------------------------------------------------------------

The use of a stent was significantly associated with lower taste impairment, difficulty swallowing/chewing and lack of appetite in patients irradiated with unilateral radiotherapy in univariate analysis and remained significant for taste and appetite in multivariate analysis ([Table 3](#t0015){ref-type="table"}).Table 3Results (p-values) of univariate and multivariate (in brackets) analysis for different radiation-associated symptoms divided into groups with unilateral and bilateral radiation technique. Factors with p-values \< 0.1 were included into the multivariate analysis.Taste impairmentDry mouthMucus in mouth/throatUnilateralBilateralUnilateralBilateralUnilateralBilateralSex0.2650.3710.7340.014 (0.021)0.1670.700Age at RT start0.053 (0.037)0.088 (0.171)0.6740.6170.8340.521Tumor site--0.789--0.303--0.762Tis/T1/T2 vs. T3/T40.5910.8930.4950.8580.1430.040 (0.163)N0 vs. N+0.7880.032 (0.024)0.1070.6770.1240.160PTV1 dose0.8510.081 (0.129)0.8810.8900.4090.598Chemo yes vs. no0.091 (0.085)0.4200.0830.7760.7410.795Current smoking at RT start0.4970.027 (0.016)0.4290.017 (0.014)0.2400.003 (0.006)Stent yes vs. no0.021 (0.018)0.6380.8820.4480.3910.491Difficulty swallowing/chewingMouth/throat soresLack of appetiteUnilateralBilateralUnilateralBilateralUnilateralBilateralSex0.2300.4700.9800.5670.4300.552Age at RT start0.8210.2640.6740.5420.2560.281Tumor site--0.040 (0.192)--0.788--0.263Tis/T1/T2 vs. T3/T40.3560.2160.0510.2450.051 (0.088)0.594N0 vs. N+0.7860.1790.3130.9020.5830.205PTV1 dose0.1710.7500.4510.3690.3720.042 (0.141)Chemo yes vs. no0.8040.3020.2010.5730.9100.260Current smoking at RT start0.0690.016 (0.075)0.4410.0130.4410.006 (0.007)Stent yes vs. no0.1790.050 (0.747)0.8940.5610.012 (0.071)0.876[^4]

In patients irradiated with bilateral neck RT, current smoking at RT start had a significant negative influence on all oral morbidity-related symptoms (no/mild vs. moderate/severe). Positive lymph node status was associated with increased taste impairment in these patients ([Table 3](#t0015){ref-type="table"}).

4. Discussion {#s0055}
=============

The dosimetric advantage of different oral stent types as well as the "stick-out" tongue technique for HNC RT has already been described in other studies [@b0040], [@b0045], [@b0050], [@b0055], [@b0060], [@b0065], [@b0070], [@b0105] ([Table 4](#t0020){ref-type="table"}). To our knowledge, this study of over 450 patients with OPC and long-term survival is the first to attempt to translate these dosimetric advantages of stent usage into a clinical benefit with regards to decreasing late symptoms in HNC patients. We found both a benefit to a tongue-deviating stent for patients treated with unilateral neck RT, and a tongue-depressing stent for patients treated with bilateral neck RT.Table 4Overview of published studies investigating oral stents for external beam head and neck radiotherapy.Author, yearAvailable publicationnTumor subsiteStent type definitionDosimetric resultToxicity outcomeFeng, 2019 [@b0040]Original paper60Sinus, gingiva, nasal lymphoma, olfactory neuroblastomaBite blockSign. lower Dmean and Dmax to the tongue, Dmax to submandibular gland and Dmean to mandible, bilateral PGs and SMGs. No difference for PTV.15% G1 mucositis, 10% G2 mucositis during RT; no taste dysfunction or xerostomia (median follow-up 25 months).Grant, 2019 [@b0045]Conference abstract20TonsilTongue-deviating stentSign. lower Dmean and V30 to oral mucosa and tongue for IMRT. No difference for IMPT. No difference for both techniques for oral mucosa and tongue D3cc.--Kil, 2017 [@b0050]Case report3BOTSign. decrease in Dmean to ant. OC, oral tongue, SPC, MPC, supraglottic larynx; sign. reduced V30/V35 of ant. OC and oral tongue and V55/60 of SPC and MPC. PTV coverage same.--Kil, 2016 [@b0055]Original paper13Tonsil, larynx"Stick-out" tongueSign. more distance between BOT/PC, tongue/hard palate and gingiva/lips. Sign. reduced Dmean to OC, tongue and lips (only for OPC). Lower V15/V30/V45 of tongue.--Nayar, 2016 [@b0060]Original paper55 (24/31)\*HNCRadiation-positioning stentSign. less dose to the maxilla in tumors of/near the mandible with stent. Also less dose to the mandible in tumors of/near the maxilla with stent, but not sign..Sign. improvement of 78% in mouth-opening with stent 1--2 months post-RT.Verrone, 2014 [@b0065]Original paper33 (19/14)\*Tongue, floor of mouthMouth-opening, tongue-depressing stentSign. lower Dmean to the maxilla and ipsilat. PG with stent, but PTV dose in this group sign. lower.Later onset of G3 mucositis with stent during RT.Mall, 2016 [@b0130]Original paper30 (15/15)\*Posterior tonguePositioning stent--Sign. higher salivary flow rates (stimulated and unstimulated) and sign. better xerostomia-related QoL with stent at 3 and 6 months post-RT.Verrone, 2013 [@b0105]Case report1TongueMouth-opening, tongue-depressing stentLower Dmean to teeth, hard palate, PGs, left SMG with stent; target coverage similar.G2 oral mucositis from day 13 of RT. Beginning of G3 xerostomia in first weeks of RT; at 6 months post-RT only G1 xerostomiaGoel, 2010 [@b0135]Original paper48 (24/24)\*TonguePositional stents--Sign. lower palatal mucositis and xerostomia with stent at 30, 45 and 60 days post-RT.Qin, 2007 [@b0070]Original paper43 (19/24)\*NPCIndividual dental stentDecrease in RT dose to the tip and body of tongue with stent.Rate of G3 oral mucositis lower with stent, G1--2 higher. Sign. less taste dysfunction with stent.[^5]

Patients treated with unilateral neck RT with a tongue-deviating oral stent for early tonsil cancer reported lower scores for taste impairment and lack of appetite. Although the difference in mean MDASI-HN score between the groups with and without oral stent might be low, there is a significant decreased proportion of patients who had moderate/severe symptoms. Less toxicity has already been reported for unilateral irradiation in cohorts of OPC [@b0110] and tonsil cancers only [@b0115], [@b0120] compared to standard bilateral RT by other authors. Despite these patients having in general a lower toxicity profile, the addition of a tongue-deviating stent further decreases long-term patient reported symptoms.

Patients treated with tongue-depressing stents and bilateral neck RT showed significantly less moderate/severe dysphagia and mouth/throat sores. Besides the overall beneficial effect on long-term toxicity, the tongue-depressing stent has been previously shown to improve patient and oral immobilization during treatment [@b0035]. This improvement in immobilization can lead to an improved image quality in MRI [@b0035], which is often fused with the planning CT for better target and organ at risk delineation. Furthermore, the increased reproducibility of patient positioning during RT may possibly contribute to a higher local tumor control rate. However, that particular study [@b0035] was conducted at baseline, mid-treatment and one month post-treatment only, and not at the end of the treatment when the radiation side effects are most severe, which could negatively impact patient tolerability of the stents. Stent compliance or patient stent experience was not formally assessed as part of this study but would be worthy of future investigation.

A limitation of this study is the non-randomization of stent use and the non-standardization of clinical factors leading to stent use decision-making. Furthermore, due to the eligibility criteria of the parent study including only patients without active disease, any positive or negative association of stent use with local control could not be assessed. However, there is evidence that stent use is beneficial in terms of dosimetric parameters of the organs at risk [@b0040], [@b0045], [@b0050], [@b0055], [@b0060], [@b0065], [@b0070], [@b0105], and we add data to suggest a clinical benefit with regards to patient reported long-term outcomes. This study is a retrospective analysis of prospectively collected data, and while randomized data is regarded as strongest from a scientific perspective, recognizing stents improve dosimetry with regards to avoidance of normal tissue, and treatment reproducibility, it is moot whether randomized data is an absolute necessity. Another limitation in our study is the wide range of individual MDASI-HN time points after RT. Although we excluded patients with only MDASI-HN assessments within the first 12 months from end of RT, others have shown there is further improvement of oral morbidity-related symptoms over time [@b0125]. However, since the time points of analyzed MDASI-HN assessments did not vary much between the groups with or without stent (Suppl. Table 5), the impact of varying time points are likely at most of minor impact.

5. Conclusions {#s0060}
==============

When safely and reliably tolerated, use of a tongue-deviating stent should be considered for selected tonsil cancer patients when treated with unilateral neck RT as it was significantly associated with improved long-term patient reported taste and appetite. Likewise, our data also suggest the select use of tongue-depressing stents for patients treated with bilateral neck RT for BOT cancers reduced long-term patient reported dysphagia and mouth/throat sores. Routine involvement of dental oncology specialists should be part of the multidisciplinary care of OPC patients.
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[^1]: \*if not indicated otherwise; BOT: base of tongue, PTV1: high dose planning target volume, n: number of patients, N+: node positive, RT: radiotherapy, SD: standard deviation

[^2]: BOT: base of tongue, SD: standard deviation.

[^3]: Significant p-values in bold.

[^4]: PTV1: high dose planning target volume, N+: node positive, RT: radiotherapy

[^5]: \*with/without oral stent. BOT: base of tongue, D: dose received by a certain treatment volume, Dmean: mean dose, G: grade, HNC: head and neck cancer, MPC: medial pharyngeal constrictor, n: number of patients, NPC: nasopharyngeal cancer, OC: oral cavity, OPC: oropharyngeal cancer, PC: pharyngeal constrictor, PG: parotid gland, PTV: planning target volume, QoL: quality of life, RT: radiotherapy, sign.: significant/ly, SMG: submandibular gland, SPC: superior pharyngeal constrictor, V: volume receiving a certain radiation dose
